HUTCHMED (China) Limited Files US NDA for ORPATHYS Plus TAGRISSO in MET-Driven EGFRm NSCLC

HUTCHMED said AstraZeneca submitted a US FDA NDA for ORPATHYS (savolitinib) plus TAGRISSO (osimertinib) in MET overexpression/amplification EGFR-mutated NSCLC after progression on an EGFR-TKI, supported by positive Phase III SAFFRON results.Material DetailsContext by AI AnalystThis is a late-stage…